Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Ranbaxy Internal Audit Disclosure Highlights FDA Policy Exceptions

This article was originally published in The Gold Sheet

Executive Summary

FDA went to court for a look at Ranbaxy’s internal audits despite its longstanding policy against routinely reviewing such documents. However, a 1996 revision made exceptions for cases like Ranbaxy’s, in which the agency is pursuing allegations of fraud.

You may also be interested in...



FDA Focuses Latest Warnings on Accountability and Root Cause

Quest for accountability and root cause seen in latest FDA warning letters. FDA, Congress pressure McNeil, J&J. 'Phantom recall' debated. Is propofol too hard for Teva, Hospira to make? Perrigo raked over tablet mix-ups. Braintree learns to fear spiders. Merck unit goes OOS. Splitting hairs over Shamrock's tablet splitting? Pierre Fabre: Three batches and you're out?

FDA Focuses Latest Warnings on Accountability and Root Cause

Quest for accountability and root cause seen in latest FDA warning letters. FDA, Congress pressure McNeil, J&J. 'Phantom recall' debated. Is propofol too hard for Teva, Hospira to make? Perrigo raked over tablet mix-ups. Braintree learns to fear spiders. Merck unit goes OOS. Splitting hairs over Shamrock's tablet splitting? Pierre Fabre: Three batches and you're out?

Data Integrity Problems Continued to Surface in Recent Warning Letters

Recent GMP warning letters featured data integrity issues.

Latest Headlines
See All
UsernamePublicRestriction

Register

PS000279

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel